High
--
Open
--
VWAP
--
Vol
--
Mkt Cap
--
Low
--
Amount
--
EV/EBITDA(TTM)
--
Total Shares
--
EV
--
EV/OCF(TTM)
--
P/S(TTM)
--
Market Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2025Q4
FY2026Q1
FY2026Q2
1.16B
+6.25%
6.428
-2.61%
977.05M
+8.82%
4.440
+164.29%
1.09B
+4.42%
5.506
-166.74%
Estimates Revision
The market is revising Upward the revenue expectations for Jazz Pharmaceuticals plc (JAZZ) for FY2025, with the revenue forecasts being adjusted by 0.31% over the past three months. During the same period, the stock price has changed by 28.89%.
Revenue Estimates for FY2025
Revise Upward
+0.31%
In Past 3 Month
EPS Estimates for FY2025
Revise Upward
+54.26%
In Past 3 Month
Stock Price
Go Up
+28.89%
In Past 3 Month
15 Analyst Rating
Wall Street analysts forecast JAZZ stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for JAZZ is 206.60 USD with a low forecast of 147.00 USD and a high forecast of 247.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
15 Buy
0 Hold
0 Sell
Strong Buy
Current: 166.910
Low
147.00
Averages
206.60
High
247.00
Current: 166.910
Low
147.00
Averages
206.60
High
247.00
UBS
Ashwani Verma
Buy
to
Neutral
downgrade
$163 -> $188
2025-11-24
Reason
UBS
Ashwani Verma
Price Target
$163 -> $188
2025-11-24
downgrade
Buy
to
Neutral
Reason
UBS analyst Ashwani Verma downgraded Jazz Pharmaceuticals to Neutral from Buy with a price target of $188, up from $163. Following the strong Phase 3 GEA update and a 25% stock move, Jazz now appears fairly valued with a balanced risk/reward profile, the analyst tells investors in a research note. The positive study meaningfully improves the outlook, but with recent oncology momentum already reflected in the valuation and no major catalysts ahead, UBS sees limited upside/downside.
Baird
Brian Skorney
maintain
$160 -> $209
2025-11-18
Reason
Baird
Brian Skorney
Price Target
$160 -> $209
2025-11-18
maintain
Reason
Baird analyst Brian Skorney raised the firm's price target on Jazz Pharmaceuticals to $209 from $160 and keeps an Outperform rating on the shares. The firm said its HERIZON-GEA001 top line appears to be a best-case scenario.
Truist
Buy
maintain
$205 -> $220
2025-11-18
Reason
Truist
Price Target
$205 -> $220
2025-11-18
maintain
Buy
Reason
Truist raised the firm's price target on Jazz Pharmaceuticals to $220 from $205 and keeps a Buy rating on the shares following "positive" HERIZON-GEA-01 topline data. Current indications alone could drive Ziihera peaks sales greater than $2B, according to the firm. However, given breadth of HER2+ cancers for which Herceptin/Enhertu are standard of care, Truist thinks there's plenty of upside from Ziihera, which the firm views as pipeline-in-a drug.
BofA
Buy
maintain
$230 -> $247
2025-11-18
Reason
BofA
Price Target
$230 -> $247
2025-11-18
maintain
Buy
Reason
BofA raised the firm's price target on Jazz Pharmaceuticals to $247 from $230 and keeps a Buy rating on the shares. Favorable Phase 3 topline data from the HERIZON-GEA-01 study in gastric cancer suggest Ziihera is an approvable drug in first-line GEA, a market the firm estimates could equate to greater than $600M in the U.S. and greater than $1.1B in global peak sales, the analyst tells investors.
Wells Fargo
NULL
to
Overweight
upgrade
$170 -> $235
2025-11-18
Reason
Wells Fargo
Price Target
$170 -> $235
2025-11-18
upgrade
NULL
to
Overweight
Reason
Wells Fargo raised the firm's price target on Jazz Pharmaceuticals to $235 from $170 and keeps an Overweight rating on the shares. The firm sees zanidatamab's gastroesophageal adenocarcinoma read out supporting it as new standard of care in GEA. Zani's success in GEA may be a readthrough to breast cancer, and Wells sees an unadjusted peak opportunity of about $3B in both indications. Data is expected in Q1 2026, potentially at ASCO GI, the firm adds.
RBC Capital
Outperform
maintain
$155 -> $194
2025-11-17
Reason
RBC Capital
Price Target
$155 -> $194
2025-11-17
maintain
Outperform
Reason
RBC Capital raised the firm's price target on Jazz Pharmaceuticals to $194 from $155 and keeps an Outperform rating on the shares. The firm notes the company announced positive topline data from HERIZON-GEA-01, and while exact numbers were not broken out, the overall survival and progression-free survival hit in the triplet, improvements across subgroups, and "clinically meaningful" benefits suggests potential for zani to become the new standard of care in GEA. Overall, the HORIZON-GEA-01 success reinforces Jazz's strategic shift towards a more diversified, oncology-focused pipeline and now provides a clearer late-stage value driver in their portfolio to help offset any future oxybate and legacy franchise softness, RBC adds.
See All Ratings
Valuation Metrics
The current forward P/E ratio for Jazz Pharmaceuticals PLC (JAZZ.O) is 7.49, compared to its 5-year average forward P/E of 8.00. For a more detailed relative valuation and DCF analysis to assess Jazz Pharmaceuticals PLC 's fair value, click here.
Forward PE
The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
Fair
5Y Average PE
8.00
Current PE
7.49
Overvalued PE
10.36
Undervalued PE
5.64
Forward EV/EBITDA
The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
N/A
5Y Average EV/EBITDA
7.58
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
8.94
Undervalued EV/EBITDA
6.22
Forward PS
The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
N/A
5Y Average PS
2.21
Current PS
0.00
Overvalued PS
2.70
Undervalued PS
1.73
Financials
Annual
Quarterly
N/A
Total Revenue
N/A
Operating Profit
N/A
Net Income after Tax
N/A
EPS - Diluted
N/A
Free Cash Flow
N/A
Gross Profit Margin - %
N/A
FCF Margin - %
N/A
Net Margin - %
N/A
ROIC
Trading Trends
Insider
Insiders areSelling! The selling amount has increased 2662.18% over the last month.
Sold
Bought
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
Bought
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Insider
Insiders areSelling! The selling amount has increased 2662.18% over the last month.
Sold
Bought
JAZZ News & Events
Events Timeline
(ET)
2025-11-17
12:00:50
Jazz Pharmaceuticals sees a 20.6% increase.
2025-11-17
10:00:12
Jazz Pharmaceuticals sees a 20.8% increase.
2025-11-17
06:16:35
Jazz Pharmaceuticals reveals key findings from HERIZON-GEA-01 trial
Sign Up For More Events
Sign Up For More Events
News
![[object Object]](https://d5bp8bijhhba2.cloudfront.net/image/cover_image/3171cb035ccebbc492cd09aa43de09ca22fda8e1b8de51e4051fa5b83e9b20cb.jpeg)
Preview
9.0
12-03NewsfilterPinnedJazz Pharmaceuticals Presents Key Ziihera Data at ASCO GI for HER2+ Cancers
![[object Object]](https://d5bp8bijhhba2.cloudfront.net/image/cover_image/20251203054032_c4cae6bcf3feafe2694c4b0cb66e9d58.jpg)
Preview
9.0
12-03PRnewswireJazz Pharmaceuticals' Ziihera Achieves Breakthrough in HER2+ Gastric Cancer Clinical Trials
Preview
6.0
11-24BenzingaUBS Lowers Jazz Pharmaceuticals Rating to Neutral, Increases Price Target to $188
Sign Up For More News
People Also Watch
FAQ
What is Jazz Pharmaceuticals PLC (JAZZ) stock price today?
What is Jazz Pharmaceuticals PLC (JAZZ)'s business?
What is the price predicton of JAZZ Stock?
What is Jazz Pharmaceuticals PLC (JAZZ)'s revenue for the last quarter?
What is Jazz Pharmaceuticals PLC (JAZZ)'s earnings per share (EPS) for the last quarter?
What changes have occurred in the market's expectations for Jazz Pharmaceuticals PLC (JAZZ)'s fundamentals?
How many employees does Jazz Pharmaceuticals PLC (JAZZ). have?